Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Healthy males or females (non-pregnant/non-lactating) aged 18 - 50 years.~* A Body Mass Index (BMI) of 18-30.~* No clinically significant abnormal serum biochemistry, haematology and urine examination values.~* A negative urinary drugs of abuse screen.~* Negative HIV and Hepatitis B and C results.~* No clinically significant abnormalities in 12-lead electrocardiogram (ECG).~* No clinically significant abnormalities in blood pressure or pulse.~* No allergy or sensitivity to clonidine or any of its excipients.~* No allergy to milk or milk derivatives.~* Subjects must provide written informed consent to participate in the study~Main Exclusion Criteria:~* Current or past medical condition that might significantly affect the pharmacokinetic or~* pharmacodynamic response to clonidine.~* Participation in a New Chemical Entity clinical study within the previous 3 months or a marketed drug clinical study within the previous 30 days.~* Pathological condition of the oral cavity that would affect administration via the buccal route.~* Raynaud's disease or other peripheral vascular disease.~* Receipt of regular medication within 14 days of the first dose that may have an impact on the safety and objectives of the study (at the Investigator's discretion).~* Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.~* Symptomatic postural hypotension evident on screening~* History or evidence of Suicidal Ideation and/or behaviour as determined by using Columbia-Suicide Severity Rating Scale (C-SSRS)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Clonidine MBT 50µg (Type: EXPERIMENTAL): Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50µg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
- Clonidine MBT 100µg (Type: EXPERIMENTAL): Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100µg single dose ,a single-dose of reference catapres 100μg tablets..
- Catapres 100μg (Type: ACTIVE_COMPARATOR): Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).